Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
APPROVAL RECEIVED FOR MARKETING OT-702 IN CHINA

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that, OT-702 (Aflibercept Intravitreous Injection, EYLEA® biosimilar), has been approved for marketing by the National Medical Products Administration (the "**NMPA**") of the People's Republic of China ("**China**") for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults.

OT-702 was developed by the Group's partner, Shandong Boan Biotechnology Co., Ltd. (山東博安生物技術股份有限公司) ("**Boan Bio**"), the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 6955). Pursuant to the cooperation and exclusive promotion agreement entered into by both parties in October 2020, the Group, together with Boan Bio, shall co-advance the phase III clinical trial of OT-702, and the Group was granted the exclusive right to promote and commercialize the product in the PRC.

OT-702, as a soluble trapping receptor, can bind to cytokines such as VEGF-A, VEGF-B and P1GF, inhibit the downstream signaling pathway of VEGFR, inhibit neovascularization, and reduce vascular permeability, thereby treating pathological neovascularization of the retina and choroid eye diseases. OT-702 is a biosimilar to EYLEA®, the globally approved indications of which include nAMD, DME, macular edema secondary to retinal vein occlusion (RVO), diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV) and retinopathy of prematurity (ROP). In China, it has been approved for the treatment of nAMD and DME. According to Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars (《生物類似藥相似性評價和適應症外推技術指導原則》) issued by CDE, OT-702 is eligible to apply for approval for all indications approved for EYLEA® in the PRC.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-702 (Aflibercept Intravitreous Injection, EYLEA® biosimilar) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, November 26, 2025

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr.Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.